Physician profile
Kenneth G Pittman
NPI 1588822431
$152,053.54
in general payments reported to CMS, 2019-2025
17 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,459 · 2020: $1,027 · 2021: $3,700 · 2022: $12K · 2023: $23K · 2024: $31K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Honoraria: $33K · Travel and Lodging: $12K · Food and Beverage: $8,304 · Consulting Fee: $5,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,622.50 |
| Honoraria | $32,738.00 |
| Travel and Lodging | $12,466.18 |
| Food and Beverage | $8,304.06 |
| Consulting Fee | $5,730.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $74,345.20 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $37,338.69 | 2025 | Jornay Pm |
| Tris Pharma INC | $17,201.06 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $10,931.07 | 2022-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $10,433.27 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $450.16 | 2019-2022 | |
| Neos Therapeutics, Lp | $400.16 | 2019-2024 | Cotempla Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $288.88 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Arbor Pharmaceuticals, INC. | $145.40 | 2019-2020 | |
| Adlon Therapeutics L.P. | $92.25 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $82.20 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.51 | 2020-2022 | |
| Axsome Therapeutics, INC. | $66.57 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $66.47 | 2024-2025 | Xelstrym, Secuado |
| Shire North American Group INC | $52.34 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $48.17 | 2024 | Relexxii |
| Avion Pharmaceuticals | $36.14 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Pittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.